glp-1 receptor agonist with dpp-4 inhibitor combination not recommended The effect of inhibitors, agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs | Cardiovascular Diabetology SGLT2 Inhibitors and GLP-1 Receptor

25 The prescribing information notes that waiting less than 30 minutes or taking with food, beverages other than plain water, or other oral medications will lessen the effect of the product

This is a large, carefully designed observational study not a randomised trial so it points to a promising signal rather than a proven benefit

This article explains the gastrointestinal effects of GLP-1 therapy and provides practical guidance for managing bowel changes during treatment

These medications are also approved for pediatric patients aged 12 and older who have obesity

The important factor to remember is that both medications and supplements are altering the hormones that signal to your brain to stop eating when you are full

For those interested in participating in clinical trials of maridebart cafraglutide, the NIHR 'Be Part of Research' registry (www.bepartofresearch.nihr.ac.uk) and ClinicalTrials.gov maintain registries of ongoing studies